AIM-HI Accelerator Fund

Home
United States
Rockville, MD
AIM-HI Accelerator Fund

Directions Website Contact the organization

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from AIM-HI Accelerator Fund, Nonprofit Organization, 5515 Security Lane, Suite 1105, Rockville, MD.

We provide oncology startups with the resources they need to drive innovative discoveries forward, out of the lab, to the clinics, and eventually to the people battling cancer.

10/09/2026

Today's the day! 🎉
The 2026 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted by AIM-HI, is happening today at the National Press Club in Washington, D.C.! We're excited for a day of inspiring conversations, fresh ideas, and recognition of outstanding leaders advancing cancer research and innovation.
Don't miss this opportunity to connect with leading minds driving progress against cancer!
Learn more: https://hubs.ly/Q04zJ0bK0

10/06/2026

We’re almost there! This Friday, the 2026 NFCR Global Summit and Award Ceremonies For Cancer Research & Entrepreneurship, co-hosted by AIM-HI, will bring together cancer researchers, innovators and advocates at the National Press Club in Washington, D.C.
Get ready for a day of inspiring ideas, meaningful connections and collaboration to accelerate the next breakthroughs in cancer research.
Learn more: https://hubs.ly/Q04zmVhR0

09/24/2026

Advancing cancer research takes visionary leaders who challenge convention, drive innovation, and create meaningful change for patients. This year, we are honored to recognize Laura Esserman, M.D., MBA, as the recipient of the 2026 AIM-HI Beacon Award for Women Leaders in Oncology. An internationally recognized breast cancer surgeon and pioneer in personalized medicine, Dr. Esserman has helped transform approaches to breast cancer research and care.

Join AIM-HI and the National Foundation for Cancer Research (NFCR) on October 9, 2026, at the National Press Club in Washington, DC, as we honor Dr. Esserman at the 2026 AIM-HI Beacon Award Ceremony, held as part of the 2026 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship.

Secure your seat and join us: https://hubs.ly/Q04ygrjM0
Read the Full Press Release: https://hubs.ly/Q04ygrdx0

09/21/2026

The AIM-HI Accelerator Fund is pleased to announce Laura Esserman, M.D., MBA, Alfred A. de Lorimier Endowed Chair in General Surgery, Director of the University of California, San Francisco (UCSF) Breast Care Center and Professor of Surgery and Radiology at UCSF, as the recipient of the 2026 AIM-HI Beacon Award for Women Leaders in Oncology. Congratulations, Dr. Esserman! 🎉

“I am deeply honored to receive the 2026 AIM-HI Beacon Award for Women Leaders in Oncology. This recognition belongs as much to the patients, collaborators, advocates, and trainees who have shaped I-SPY, WISDOM, RECAST, and REWIRE DCIS, and everything we have built together as it does to me. My hope has always been that we can move cancer care toward something more personalized, less harmful, and adaptive to risk and response. We can do it much faster by working across institutions and disciplines rather than alone, and by being willing to challenge long-held paradigms and acting upon what the trials are teaching us in real time. The goal is to keep learning – and to test and provide new options when our patients need them most. I am grateful to the AIM-HI Accelerator Fund and the National Foundation for Cancer Research for this honor,” said Dr. Esserman.

Dr. Esserman will be honored at the 2026 AIM-HI Beacon Award Ceremony at the National Press Club in Washington, DC, on October 9, 2026, as part of the 2026 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship.

Read the press release: https://hubs.ly/Q04x_Zc_0
Join us in honoring Dr. Esserman: https://hubs.ly/Q04x_Zk70

08/26/2026

AIM-HI is pleased to share the upcoming 2026 Technology Showcase, hosted by the Frederick National Laboratory for Cancer Research.

📅 September 9, 2026📍 Frederick, Maryland

This free event will highlight NCI and FNL technologies available for licensing and collaboration, featuring inventor presentations, networking and partnering opportunities, educational panels, funder pitches, and more.

The showcase brings together companies, investors, entrepreneurs, technology scouts, and others across the biotech community to connect and explore opportunities in cancer research and technology.

Learn more and register: https://hubs.ly/Q04vjj0p0

08/06/2026

🔬 A major scientific milestone for AIM-HI portfolio company Degron Therapeutics.
Research led by Degron Therapeutics and ShanghaiTech University has been published in Nature, highlighting a promising molecular glue degrader designed to target HuR—a protein long considered difficult to drug.
The study revealed how targeted degradation of HuR may suppress BRAF-mutant colorectal cancer and potentially help overcome resistance to BRAF inhibitors, pointing to a promising new direction for difficult-to-treat cancers.
Degron Therapeutics was a winner of the 2023 AIM-HI BRACE Award Venture Competition. We are proud to see the company continue translating innovative science into potential new approaches for difficult-to-treat cancers.
Read the full release: https://hubs.ly/Q04s86RW0

07/08/2026

We are proud to share that Dr. Sujuan Ba, CEO & Co-Founder of AIM-HI and President & CEO of the National Foundation for Cancer Research, will speak at Excellentium 2026, hosted by Global Biotech Revolution.

Dr. Ba will join the panel “Building and Motivating Teams to Deliver Impact”, moderated by Elisabeth Guy-Dubois, along with Alexandra Zemp, Olivier Soula, Dr. Ruth Shah and Nigel Sheail. The discussion will explore how leaders can build and motivate teams, make strategic decisions, and lead for impact while empowering the next generation of biotech, life sciences, and healthcare leaders.

Through our annual AIM-HI Venture Competitions and other programs, AIM-HI supports scientist-entrepreneurs working to advance innovative cancer therapies and technologies. By helping early-stage oncology innovators strengthen their strategy, build connections, and access critical resources, AIM-HI works to bridge the gap between research breakthroughs and real-world patient impact.

Learn more about Excellentium 2026: https://hubs.ly/Q04nRNw30
Learn more about AIM-HI’s work to support early-stage oncology innovators: https://hubs.ly/Q04nRDPz0

07/02/2026

AIM-HI portfolio company Clasp Therapeutics has announced encouraging preclinical data for CLSP-5282, a first-in-class KRas-directed T-cell engager (TCE) designed to target KRas G12V-mutant cancers.

The data demonstrated:
🔹Potent mutation-specific tumor killing
🔹Strong anti-tumor activity in preclinical models
🔹Enhanced activity in tumors resistant to KRas inhibitors
🔹Potential for rational dual-KRas targeting

Clasp plans to submit an Investigational New Drug (IND) application in 2026, marking an important step toward clinical development.

Congratulations to the Clasp team on this milestone.

Read more: https://hubs.ly/Q04nkbGr0

06/09/2026

🚀 Congratulations to the 2026 AIM-HI Venture Competition Semi-Finalists!

These seven pioneering companies have emerged with bold ideas and breakthrough technologies aimed at transforming the future of oncology (listed in alphabetical order):
🔹Cellinfinity Bio
🔹Nemea Therapeutics
🔹RedPoint Oncology
🔹Resolute Science
🔹Talus Bio
🔹Trojan Bio
🔹VerImmune

AIM-HI is proud to support visionary scientist-entrepreneurs by connecting them with funding opportunities, expert mentorship, and a global network of oncology innovation leaders accelerating the path from breakthrough science to treatments that reach patients.

Learn more about the competition: https://hubs.ly/Q04kDkYt0

| OncoDaily

04/21/2026

🚨 NIH Webinar: A First-in-Class Non-Opioid Therapy for Substance Use Disorders

🗓 April 29, 2026 | ⏰ 11:00 AM – 12:00 PM (EST)

Join NIH (NIDA & NCATS) to learn about a novel small molecule targeting the dopamine D3 receptor—designed to block drug reward pathways without addictive liability.

With IND designation secured and a Phase 1 trial upcoming, this approach offers a promising alternative to opioid-based treatments and addresses unmet needs in stimulant and polysubstance use disorders.

💡 Ideal for biotech/pharma leaders, investors, and BD professionals exploring partnership opportunities.

🔗 Register to attend: https://hubs.ly/Q04cZ94l0

Address

5515 Security Lane, Suite 1105
Rockville, MD
20852

Website

https://linktr.ee/aimhiaccelerator, https://aim-hiaccelerator.org/

Alerts

Be the first to know and let us send you an email when AIM-HI Accelerator Fund posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to AIM-HI Accelerator Fund:

Want your organization to be the top-listed non profit organization in Rockville?